Summarized by / Author: Usama bin Nasir, MD Contribution To Literature: WARFASA trial established role of aspirin for prevention of recurrent VTE in patients who have completed 6-18 months course of anticoagulation and were no longer on it. Guidelines Adaptation According to ACCP (CHEST) Antithrombotic Therapy for VTE Disease 2016 guidelines, in patients with an unprovoked proximal..
Use of novel oral anticoagulation agents for VTE was established after a series of non-inferior trials that compared NAOCs with conventional therapy of LMWH and warfarin. The AMPLIFY trial was a randomized non-inferior trial that studied the usefulness of apixaban in preventing the recurrence of VTE after initial episode compared to conventional therapy of warfarin…
Let’s talk methodology… In this randomized, open-label, non-inferiority trial, the authors analyze a primary composite outcome that includes recurrent VTE and major bleeding in cancer patients taking edoxaban, a factor X inhibitor developed by the study sponsor, Daiichi-Sankyo. They conclude that when compared with LMWH, edoxaban is non-inferior for the aforementioned composite outcome. Because composites..